Great News! Semaglutide & Tirzepatide Now Available
LetsLose, Weight Loss & Wellness proudly introduces Semaglutide and Tirzepatide, cutting-edge GLP medications for weight management. Initially crafted to combat type 2 diabetes, these medications, known commercially as Ozempic and Wegovy, have become quite popular for their effectiveness in promoting weight loss. At LetsLose, we provide compounded versions of these acclaimed medications. To prioritize patient safety, all GLP medications are sourced directly from an FDA-regulated pharmacy in the U.S.
Understanding Semaglutide & Tirzepatide
Semaglutide functions by mimicking the action of an incretin hormone called glucagon-like peptide-1 (GLP-1), which plays a crucial role in blood sugar regulation. GLP-1 is released after eating and stimulates insulin production, which lowers blood sugar levels. Additionally, GLP-1 slows gastric emptying, which prolongs the feeling of fullness after eating.
Tirzepatide works by combining the actions of two incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are vital in regulating blood sugar levels. Like GLP-1, GIP is released after eating and also stimulates insulin production, contributing to lower blood sugar levels. The dual mechanism of Tirzepatide not only enhances insulin production but also suppresses glucagon release, leading to more effective blood sugar control. Furthermore, by acting on both GLP-1 and GIP receptors, Tirzepatide effectively slows gastric emptying and increases the feeling of fullness, which can contribute to weight loss.
How GLP’s Work for Weight Loss
Semaglutide: The primary mechanism through which Semaglutide facilitates weight loss is its ability to suppress appetite. By activating GLP-1 receptors in the brain, it influences the appetite control center to reduce hunger and increase satiety. This leads to a decrease in overall calorie intake, helping individuals to lose weight. Furthermore, semaglutide’s effect on slowing gastric emptying contributes to a prolonged sensation of fullness, further aiding in reducing food intake.
Tirzepatide: With Tirzepatide, weight loss is achieved through its unique dual-action mechanism targeting both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual agonism enhances its capacity to control appetite and increase satiety more effectively than single agonists. By stimulating these receptors in the brain, Tirzepatide significantly diminishes hunger signals and promotes a feeling of fullness, leading to reduced calorie consumption and subsequent weight loss. Additionally, similar to semaglutide, Tirzepatide slows gastric emptying, extending the sensation of satiety and further contributing to decreased food intake. This comprehensive approach not only aids in reducing body weight but does so with a potency that surpasses that of treatments targeting GLP-1 alone.
Considerations
While GLP’s medications are generally a good solution for losing weight, GLP-1 (Glucagon-Like Peptide-1) medications may not be suitable for certain individuals with a personal or family history of multiple endocrine neoplasia type 2A (MEN 2A), a genetic condition predisposing them to tumors in multiple endocrine glands. Additionally, GLP-1 agonists are generally not recommended for those with a history of medullary thyroid carcinoma (MTC), as studies have shown an association with thyroid tumors in rats.